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Abstract: Abdominal ultrasound is frequently performed as part of initial staging of canine mammary tumors. The aims of this study
were to describe abdominal ultrasonographic findings present at diagnosis of mammary tumors in dogs and to assess their value for
associations with histopathological results and treatment outcome. The medical records of 201 female dogs diagnosed with mammary
tumors that had abdominal ultrasonography performed as part of their initial clinical evaluation were reviewed. Histopathological
diagnosis of malignant mammary tumors was obtained in most cases (86%; 172 cases). One hundred and fifty-seven animals (78%)
had some ultrasonographic abnormality. A total of 338 ultrasonographic changes were identified, and the spleen was the organ with the
highest frequency of ultrasonographic changes (20%), followed by the uterus (18%) and the liver (16%). Abdominal ultrasonography
abnormalities were not associated with mammary tumor malignancy (OR = 1.7; P = 0.27). Ultrasonographic evidence of enlarged
intraabdominal lymph nodes was associated with metastases in surface regional lymph nodes (P < 0.05). Dogs with regional metastasis
were more likely to present some abdominal ultrasonographic change (OR = 6.1; P = 0.04). Animals with ultrasonographic evidence of
intraabdominal lymph node enlargement presented shorter survival after mastectomy. Abdominal ultrasonographic abnormalities are
common in dogs with mammary tumors and are not associated with malignancy. However, the presence of intraabdominal lymph node
enlargement identified by ultrasound may be associated with regional metastasis and shorter survival rates.
Key words: Dog, imaging, lymph node, metastasis, prognosis, staging

1. Introduction
Mammary tumors are the most frequent neoplasm in
nonspayed female dogs or those spayed after the second estrus.
About 50% of them are malignant [1,2]. Clinical staging of
dogs with mammary tumors is based on the TNM system
(tumor size, lymph node, and metastasis) established by the
World Health Organization for canine mammary tumors [3].
The presence of metastatic disease at the time of diagnosis is
associated with worse prognosis. In order to identify distant
metastatic disease, imaging diagnosis is frequently part of the
initial staging [1].
The lungs are the most common site for distant metastasis
and three-projection thoracic radiographs remain the mainstay
for staging the thorax/lungs in dogs with suspected malignant
mammary tumors [4]. Although less common than lung
metastases, metastatic disease in the abdominal organs, such
as the liver, urinary bladder, and uterus, have been reported in
dogs with mammary tumors, justifying ultrasonography as a
screening tool for investigation of abdominal metastasis [5,6].

Several studies have investigated the utility of
abdominal ultrasonography and its impact on outcome
in dogs with tumors such as osteosarcoma, soft tissue
sarcoma, and mast cell tumor [7–9]. To the authors’
knowledge, there are no similar studies on mammary
tumors in dogs, despite abdominal ultrasonography being
routinely requested as part of the initial clinical evaluation
of these patients.
The aims of this study were to describe the frequency
and types of abdominal ultrasonography changes at
the time of diagnosis of the mammary tumor in female
dogs, to associate these results with mammary tumor
histopathology and clinical outcome, and to assess the
chance of an abdominal ultrasonographic abnormality
based on the dog’s age and mammary tumor characteristics.
2. Materials and methods
A retrospective analysis was conducted at the Veterinary
Teaching Hospital of the Federal University of Parana
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(UFPR), Curitiba, Brazil. Medical records from the Small
Animal Oncology Service were reviewed to identify
female dogs with mammary tumors between 2011 and
2013. Dogs with histopathologically confirmed mammary
neoplasia (after unilateral mastectomy) and that were
evaluated by abdominal ultrasonography for staging at
the time of initial tumor diagnosis were included in the
study. Dogs with nonneoplastic mammary tumors (such
as mastitis or mammary hyperplasia), dogs with clinical
signs of inflammatory mammary carcinoma, dogs that
did not receive surgical treatment (mastectomy), and dogs
with clinical comorbidities at the time of clinical diagnosis
of the mammary tumor were excluded.
The breed, age, spaying status, size of the tumor, and
thoracic radiographic findings (three-view thoracic
radiographies taken at the time of mammary tumor
diagnosis) for each dog were recorded in the database. Age
groups were 0–5 years, >5–8 years, >8–12 years, and >12
years.
Mammary tumor size was classified according to
maximum diameter as follows: T1 (<3 cm), T2 (3–5 cm),
and T3 (>5 cm) [3]. Results from the histopathological
examination of the resected mammary tumor and regional
lymph node (superficial inguinal or axillary) were also
reviewed. For the evaluation of clinical outcome, the
survival time after mastectomy was recorded. The owners
were contacted 2 years after the mastectomy of their dogs
and animals were classified as follows: death due to tumorrelated problems (recurrence or metastasis). death due to
other diseases. death due to unknown reasons. or alive.
2.1. Abdominal ultrasonographic evaluation
All dogs had abdominal ultrasonographic exams
performed and interpreted by radiologists of the imaging
diagnosis service of our veterinary teaching hospital. The
standard approach to a systematic abdominal ultrasound
evaluation in dogs was performed using one of two highresolution ultrasound machines (MyLabTM30 Vet Gold,
Esaote, Italy or SONIX OP, Ultrasonix Ltd., Richmond,
Canada) with convex and linear transducers, ranging from
2.5 to 14 MHz, according to the size of the animal and the
organ to be evaluated.
Ultrasonographic reports were reviewed to determine
the presence of changes according to the organ or organ
system involved (liver, gall bladder, spleen, urinary
tract, gastrointestinal tract, adrenal glands, lymph
nodes, pancreas, and reproductive tract). Findings were
categorized into the following categories: change in organ
size; alteration in echo texture or echogenicity, mass, or
nodular appearance; alteration in architecture of organs,
such as layering; cyst formation; and presentation of
intraluminal substances.
Analysis of the ultrasonographic changes was based on
the methodology reported in previous studies [7,10].

2.2. Statistical analysis
Categorical variables were reported as frequencies. The
association between ultrasonographic findings and
histopathological results (malignant or benign mammary
tumor and regional lymph node status) was evaluated
using the chi-square test. Logistic regression analysis was
used to identify significant predictors of the probability of
a dog having an abnormal ultrasound result. Predictors
were age group and mammary tumor characteristics
(tumor size and histopathological results). These results
are presented as odds ratios (ORs).
Kaplan–Meier survival curves were used to estimate
the survival of the dogs in the period up to 24 months after
the mastectomy, considering the ultrasound abnormalities
present at the time of tumor diagnosis. Dogs that did not
die due to the mammary tumor or that did not die within
the 24 months of follow-up of this study were censored
in the analysis, obtaining the cumulative survival curve.
The survival results were compared using the log-rank test.
Commercially available software was used for all statistical
analyses (IBM SPSS Statistics 22.0, IBM Corp., Armonk,
NY, USA). For all statistical analyses significance was set
at P < 0.05.
3. Results
Two hundred and one female dogs were included in the
study; 160 (80%) were not spayed and 41 (20%) were
spayed after the second estrus cycle. The age at mammary
tumor diagnosis ranged between 3 and 17 years with a
mean of 10 ± 2.45 years. There were 148 (74%) purebred
dogs and 53 (26%) mixed-breed dogs. The most common
purebreds observed were Poodle (n = 44/201; 22%) and
Cocker spaniel (n = 18/201; 9%).
Ninety-two dogs (46%) had T1 tumors (<3 cm), 51
(25%) T2 tumors (3–5 cm), and 58 (29%) T3 tumors (>5
cm). There were 172 (86%) dogs with malignant mammary
tumors and 29 (14%) with benign mammary tumors.
The most common malignant tumor was papillary
adenocarcinoma (n = 70/201; 35%). Other histologic
types were complex adenocarcinoma (n = 42/201;
21%), simple adenocarcinoma (n = 22/201; 11%), cystic
adenocarcinoma (n = 16/201; 8%), solid adenocarcinoma
(n = 7/201; 3%), tubular adenocarcinoma (n = 6/201; 3%),
undifferentiated mammary carcinoma (n = 3/201; 1%),
mammary carcinosarcoma (n = 2/201; 1%), mammary
osteosarcoma (n = 2/201; 1%), squamous carcinoma (n =
1/201; <1%) and undifferentiated mammary sarcoma (n =
1/201; < 1%). The benign tumors included benign mixed
tumor (n = 9/201; 4%), papillary adenoma (n = 6/201; 3%),
complex adenoma (n = 5/201; 2%), cystic adenoma (n =
4/201; 2%), simple adenoma (n = 4/201; 2%), and solid
adenoma (n = 1/201; <1%).

809

MATOS DA SILVA et al. / Turk J Vet Anim Sci
Twenty-one dogs (12% of 172 female dogs with
malignant tumors) had histopathologically confirmed
regional lymph node metastasis (18 had metastatic
superficial inguinal lymph node and three had metastatic
axillary lymph node). Three-view thoracic radiography
was performed at the time of mammary tumor diagnosis.
Seven animals (n = 7/201; 3%) presented radiographic
findings of pulmonary metastasis and all had malignant
mammary tumors confirmed histopathologically.
One hundred and fifty-seven patients (n = 157/201;
78%) had an abdominal ultrasonographic abnormality
identiﬁed, while 44 (22%) received normal ultrasound
reports. A total of 338 ultrasonographic changes were
recorded. The spleen was the most commonly affected
organ, accounting for 67 (20%) of 338 changes. The uterus
was the second most affected organ (n = 60/338; 18%). Of
the 160 intact female dogs, 37.5% (60/160) had uterine
ultrasound abnormalities. The remaining reported organ
changes involved the liver (n = 55/338; 16%), gallbladder (n
= 37/338; 1 %), ovaries (n = 31/338; 9%), adrenal glands (n
= 29/338; 9%), kidneys (n = 29/338; 9%), intraabdominal
lymph nodes (n = 17/338; 5%), urinary bladder (n = 9/338;
3%), stomach (n = 2/338; <1%), pancreas (n = 1/338;
<1%), and colon (n = 1/338; <1%). All ultrasonographic
alterations are described in Table 1.
Forty-four animals (n = 44/201; 22%) had an
ultrasonographic abnormality suggestive of a neoplasm,
suggesting mammary tumor metastasis as a differential
diagnosis. These changes were observed in the spleen,
liver, adrenal glands, kidneys, and intraabdominal lymph
nodes, accounting for 49 abnormalities (five animals had
ultrasonographic changes suggestive of neoplasms in more
than one organ). Three animals (two with ultrasonographic
changes suggesting liver neoplasm, one adrenal gland
neoplasm, and one spleen neoplasm) had a benign
mammary tumor and were therefore nonmetastatic. A
biopsy was not performed in any of the abdominal organs
to confirm neoplasm.
Three dogs with a suspected intraabdominal metastatic
neoplasia (two with suspected spleen neoplasm and one
with suspected kidney neoplasm) presented pulmonary
metastasis in thoracic radiographies. The other 41 animals
with possible intraabdominal metastasis did not show
thoracic radiographic metastasis.
There were no associations between any ultrasound
abnormality (χ² = 0.64, P > 0.05) or ultrasonographic
suggestion of neoplasms (χ² = 2.6, P > 0.05) and mammary
tumor histopathology results (benign or malignant).
However, the presence of enlarged intraabdominal lymph
nodes was statistically associated with the presence of
regional lymph node (inguinal or axillary) metastasis,
confirmed by histopathology after mastectomy (χ² = 7.13;
P < 0.05).
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Logistic regression showed that the likelihood of an
abnormal abdominal ultrasonographic result increased
significantly with the age of the animal (P < 0.05). When
compared to animals aged up to 5 years, female dogs aged
between 5 and 8 years were nine times (OR = 8.6) more
likely to present with abdominal ultrasonographic changes.
Female dogs aged between 8 and 12 years and older than
12 years were respectively 24 times (OR = 24.1) and 43
times (OR = 43.2) more likely to present with abdominal
ultrasonographic abnormalities.
There was an association between regional lymph
node metastasis and abdominal ultrasound abnormalities
(P < 0.05). Dogs with metastatic regional lymph nodes
were six times (OR = 6.1) more likely to present some
abdominal ultrasonography change. Tumor size and
tumor malignancy were not associated with abdominal
ultrasound abnormalities (P > 0.05). The data on
probability predicted by the multivariate logistic regression
are presented in Table 2.
Unilateral mastectomy was performed in all dogs
included in the present study. In 54 dogs (34% of the 160
intact), ovariohysterectomy (OH) was performed at the
same time as the mastectomy. All dogs that underwent
OH showed uterine and/or ovarian abnormalities by
abdominal ultrasonography.
Two years after the mammary tumor diagnosis and
mastectomy, 97 dogs (48%) were alive, 26 (13%) had
died due to unknown causes, 22 (11%) had died due to
mammary tumor-related causes, 15 (8%) had died due to
causes nonrelated to the mammary tumor, and 41 (20%)
dogs were lost to follow-up.
When including only the 160 female dogs for which it
was possible to obtain data on survival, 97 (60%) were still
alive two years after mammary tumor diagnosis, while 63
(40%) had died. Of the 63 dogs that died, 58 (n = 58/63;
92%) had a malignant mammary tumor, and only 5 (n =
5/63; 8%) had a benign mammary tumor. However, there
was no statistically significant difference between tumor
malignancy and survival at 2 years (χ² = 2.96, P > 0.05).
The ultrasonographic identiﬁcation of enlarged
intraabdominal lymph nodes or any changes suggesting
neoplastic processes were statistically associated
with shorter 2-year survival (long-rank test P < 0.05)
(Figures 1A and 1B). Although dogs with an abdominal
ultrasonographic abnormality in the liver or spleen
showed a tendency to shorter survival during the 2 years
after mastectomy, this was not statistically signiﬁcant
(long-rank test P > 0.05) (Figures 1C and 1D).
4. Discussion
In this study population, most dogs presented abdominal
ultrasonographic abnormalities at the time of mammary
tumor diagnosis. The prevalence of malignant mammary
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Table 1. Frequencies, type of alteration, and probable diagnosis of abdominal ultrasonographic findings, according to organ involved,
in 201 female dogs with mammary tumors.
Organ

Type of ultrasonographic alteration

Most likely ultrasonographic diagnosis

Spleen

67 (20%)
Heterogeneous with hypoechoic nodules
interspersed

Nodular lymphoid hyperplasia or
extramedullary hematopoiesis

37

Heterogeneous with one or two
hypoechoic nodules up to 2 cm

Nodular hyperplasia, hematoma,
abscess or neoplasm†

17

Perivascular hyperechoic focal areas

Myelolipoma

8

Increased size

Splenomegaly

4

Decreased echogenicity

Inflammatory or infectious process

1

Significant intraluminal fluid

Pyometra, mucometra, hydrometra, or
hematometra

33

Thickened uterus wall with cysts

Cystic endometrial hyperplasia

27

Uterus

60 (18%)

Liver

55 (16%)
Decreased echogenicity

Inflammatory or infectious process

17

Increased size

Hepatomegaly

10

Heterogeneous with hypoechoic nodules
interspersed

Nodular regenerative hyperplasia

9

Hyperechoic and increased size

Steroid hepatopathy or hepatic steatosis

7

Decreased size

Microhepatica

5

Focal heterogeneous mass with cystic area

Neoplasm process†

5

Increased intraluminal echogenicity

Biliary sludge or biliary stasis

33

Choleliths

Cholelithiasis

4

Gallbladder

37 (11%)

Ovary

31 (9%)
Multiple cysts

Polycystic ovary

31

Adrenal glands

29 (9%)
Increased size (unilateral)

Adrenal hyperplasia (unilateral)

14

Presence of nodule(s)

Neoplasm process†

8

Increased size (bilateral)

Adrenal hyperplasia (bilateral)

7

Indistinct corticomedullary junction

Nephropathy (probably chronic)

14

Increased cortical echogenicity

Nephropathy or incidental finding

8

Calculi

Kidney calculi

3

Presence of nodule(s)

Neoplasm process

2

Presence of cyst

Kidney cyst

1

Decreased size

Kidney hypoplasia

1

Kidney

29 (9%)

†

Lymph nodes

Urinary bladder

Frequency (n = 338)
and percentage

17 (5%)
Enlarged and heterogeneous iliac lymph
nodes

Inflammatory or neoplasm process†

14

Enlarged mesenteric lymph nodes

Inflammatory or neoplasm process†

3
9 (3%)
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Table 1. (Continued).
Bladder stones

Urolithiasis

5

Thickened bladder wall

Cystitis

4

Stomach

2 (<1%)
Thickened stomach wall

Gastritis

2

Pancreas

1 (<1%)
Decreased echogenicity

Pancreatitis

Thickened colon wall

Colitis

1

Colon

1 (<1%)
1

Alteration that had as differential diagnosis a metastasis of the mammary tumor, but biopsy was not performed to confirm.

†

Table 2. Multivariate logistic regression of the likelihood of abdominal ultrasound abnormalities among age groups, mammary tumor
size, tumor malignancy, and presence of regional lymph node metastasis.
Logistic regression
Variables
Age (years)
Histologic classification of
mammary tumor
Mammary tumor size

Odds ratio
Category

Estimate

Chi-square

P-value

Effect

OR

CI 95%

5–8

–0.1268

0.0784

0.7795

5–8 vs. up to 5

8.6

0.7

103.7

8–12

0.9073

5.5773

0.0182*

8–12 vs. up to 5

24.1

2.2

266.5

>12

1.4923

8.1933

0.0042*

>12 vs. up to 5

43.2

3.2

581.4

Malignant

0.2791

1.1839

0.2766

Malignant vs. Benign

1.7

0.6

4.8

T2

–0.1834

0.4644

0.4956

T2 vs. T1

0.4

0.2

1.0

T3

–0.5331

3.7926

0.0515

T3 vs. T1

0.3

0.1

0.7

0.9019

4.0902

0.0431*

Yes vs. No

6.1

1.1

34.9

Regional lymph node metastasis Yes

* Values with significant difference between groups. Probability of ultrasonographic changes was higher in older animals and those with
regional lymph node metastasis.
OR = Odds ratio. CI = Confidence interval.

tumors was excessively high and the ultrasound exam as
a tool for intraabdominal staging identified metastatic
suspicious lesions in 22% of the cases, these being related
to lower patient survival. These results support the
indication for abdominal ultrasonographic evaluation in
female dogs with mammary tumors.
The influence of age on the presence of abdominal
ultrasonographic changes was evident in this study, in
agreement with previous studies. Interpretation of the
results of abnormalities, especially in older animals,
should be done carefully and in association with other
tests, since many ultrasound findings may not be clinically
relevant [10–12]. The spleen was the organ with the
highest prevalence of alterations, followed by the uterus
and liver. Studies that evaluated the abdominal ultrasound
findings in dogs with different tumors also pointed to the
spleen and liver as the organs with the greatest number of
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abnormalities [7,8]. It is noteworthy that the large number
of uterine abnormalities detected in the present study is
related to the characteristics of the studied population,
which was composed of mostly nonspayed females.
Although the association between ultrasonographic
abnormalities of the reproductive tract and characteristics
of the mammary tumors was not analyzed in this study,
one should consider the influence of ovarian hormones
on the etiology of these tumors [5]. The benefits of
OH at the time of mastectomy in female dogs with
mammary tumors is controversial. There is evidence that
dogs with benign tumors that undergo OH at the time
of mastectomy have a lower risk of mammary tumor
recurrence. However, for dogs with malignant tumors,
the benefit of OH along with mastectomy seems to be
dependent on serum estradiol and/or tumor estrogen
expression [13,14].

MATOS DA SILVA et al. / Turk J Vet Anim Sci

Figure 1. Kaplan–Meier survival curves demonstrating the effect of the identiﬁcation of (A) enlarged intraabdominal lymph node
(visible by ultrasound) and (B) any abdominal ultrasonographic abnormality suggesting neoplastic process, or identiﬁcation of
ultrasonographic abnormalities affecting the (C) liver or (D) spleen in 201 female dogs with mammary tumor. Twenty-four months after
ultrasound examination and mastectomy, the percentage of alive animals was lower in the “yes” groups (with ultrasonographic changes)
than in the “no” group (without ultrasonographic changes). Significant statistical differences (log-rank test) were found in A and B.

In this study, one-third of the dogs that were not yet
spayed underwent OH at the time of mammary tumor
removal. For all of these patients an ultrasonographic
diagnosis of uterine and/or ovarian abnormality
was determined. The result of the ultrasonographic
examination probably influenced the decision to carry out
OH for these patients. The ultrasonographic abnormalities
detected, such as cystic endometrial hyperplasia,
pyometra, mucometra, and polycystic ovaries, are

conditions potentially related to estradiol expression [15].
Thus, ultrasonographic examination may be an auxiliary
screening tool to select female dogs with mammary
tumors that will benefit from OH alongside mastectomy.
The main indication of preoperative abdominal
ultrasonography in dogs with tumors is for investigation
of metastases as part as staging. The presence of metastasis
alters the prognosis and can influence the treatment
decision [7,9,16]. However, in dogs with mammary
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tumors, there is minimum information on the results
of ultrasonography for the investigation of abdominal
metastases, since thoracic radiographic examination is
often the only imaging test recommended for staging of
these patients [5,16]. Published necropsy data indicate that
the liver, kidneys, spleen, adrenal glands, and pancreas are
the most common metastatic abdominal organs in dogs
with noninflammatory mammary carcinomas [6,17].
In the present study, according to the ultrasonographic
evaluation, the intraabdominal lymph nodes, spleen, liver,
kidneys, and adrenal glands were the organs with suspected
metastatic lesions. However, an important limitation of this
study is that none of the suspected lesions were biopsied
for cytopathological or histopathological confirmation of
neoplasms. It is noteworthy that only three dogs with an
ultrasound result suggestive of abdominal metastasis also
presented radiographic signs of pulmonary metastases.
The suspicion of distant metastasis, irrespective of tumor
size or regional metastasis, means the dog with mammary
tumors is classified at stage V, the highest stage in the TNM
classification [3]. Therefore, abdominal ultrasonography
findings may lead to changes in the preoperative staging of
dogs with mammary tumors.
On the other hand, three dogs that presented
ultrasound signals suggestive of metastasis in the liver,
adrenal glands, and spleen were diagnosed with a benign
mammary tumor and thus were not metastatic. The followup of those animals with ultrasound images suggestive
of neoplasm, with repetition of the examination, as well
as the use of advanced methods of diagnostic imaging,
such as computed tomography, could contribute to the
differentiation of metastatic lesions of benign changes.
It should also be considered that the ultrasonographic
image of nodules or masses may not represent a metastatic
process but a primary tumor. A previous study reported 3%
of concomitant primary neoplasms diagnosed incidentally
by imaging tests required for staging of dogs with soft
tissue sarcomas and nasal or brain tumors [8].
Although the malignancy of lesions detected by
ultrasonography was not confirmed, the fact that dogs
with ultrasonographic lesions suggestive of a neoplastic
process presented lower survival after mastectomy
suggests that these alterations were potentially more severe
than those not suggestive of neoplasms. It is important to
note that most of the ultrasonographic changes suggestive
of neoplasm corresponded to an increase in the size
of intraabdominal lymph nodes, especially the medial
iliac lymph nodes (Table 1). The presence of enlarged
intraabdominal lymph nodes, independent of other
ultrasound findings, was also associated with shorter
survival, as well as the presence of regional superficial
lymph node metastasis (inguinal or axillary) resected with
the mammary chain during mastectomy.

814

Metastatic regional lymph nodes are an important
negative prognostic factor in dogs with mammary tumors
[18–20]. The association between an increase in the size of
intraabdominal lymph nodes verified by ultrasonography
and the presence of metastasis in superficial regional lymph
nodes suggests that abdominal ultrasonography can help
determine the metastatic potential of the mammary tumor
prior to mastectomy. It is thought that mammary lymphatic
drainage in female dogs with mammary tumors differs
from those without tumors; in particular, animals with
nodules in the third mammary pair may present lymphatic
drainage to the medial iliac lymph node (intraabdominal)
in addition to the inguinal and axillary lymph nodes [21].
Therefore, our results suggest that ultrasound evaluation
of iliac lymph nodes should be recommended in dogs
with mammary nodules even if there are no changes in
superficial regional lymph nodes.
Dogs with regional lymph node metastasis were
significantly more likely to present some type of abdominal
ultrasonographic abnormality, which may reflect some
systemic involvement due to the metastatic process,
demonstrated by abnormalities in the size and architecture
of abdominal organs. However, biopsy techniques or
advanced diagnostic imaging are required to prove this.
Increased tumor size is associated with increased
malignancy in dogs with mammary tumors [22]. However,
tumor malignancy and tumor size did not influence the
occurrence of abdominal ultrasound abnormalities in
this study, probably because these tumor characteristics
reflect greater local aggressiveness of the tumor and do
not necessarily compromise distant organs, especially
if lymphatic or hematogenous metastasis has not yet
occurred [1,5,19].
Survival analysis was performed in dogs with
intraabdominal lymph node enlargement visible by
ultrasound imaging and in those with any alterations
suggesting an abdominal neoplastic process. Survival
evaluation was also performed for dogs that presented
with ultrasonographic changes in the spleen and liver,
since they were the organs with the highest frequency of
alterations, excluding the uterus. A previous study found
significantly lower survival in dogs with osteosarcoma and
ultrasonographic changes in the liver [7]. In our study,
ultrasonographic changes in either the liver and spleen
had no significant influence on survival, although the
frequency of death was greater in dogs with some alterations
in these organs 2 years after mastectomy (Figures 1C and
1D). Further studies are needed to verify whether these
changes are not actually confounding variables, unrelated
to mammary tumors, or represent some hidden metastatic
process in these patients [7].
In summary, there is a high frequency of abdominal
ultrasonography abnormalities in dogs with mammary
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tumors. Although these changes are not related to the
malignancy or size of the mammary tumor, attention
should be paid to the abnormalities suggestive of neoplastic
processes, especially those related to intraabdominal
lymph node enlargement. The presence of an enlarged
intraabdominal lymph node identified by ultrasonography
is associated with superficial regional lymph node

metastasis and decreased survival of female dogs with
mammary tumors. Abdominal ultrasound should be
included as part of the staging of dogs with mammary
tumors; however, abnormal ultrasound findings should
be interpreted with caution when there is no histological
confirmation of these lesions.
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